Please use this identifier to cite or link to this item:
Title: Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study
Author: Fedirko, Veronika
Tran, Hao Quang
Gewirtz, Andrew T.
Stepien, Magdalena
Trichopoulou, Antonia
Aleksandrova, Krasimira
Olsen, Anja
Tjønneland, Anne
Overvad, Kim
Carbonnel, Franck
Boutron-Ruault, Marie-Christine
Severi, Gianluca
Kühn, Tilman
Kaaks, Rudolf
Boeing, Heiner
Bamia, Christina
Lagiou, Pagona
Grioni, Sara
Panico, Salvatore
Palli, Domenico
Tumino, Rosario
Naccarati, Alessio
Peeters, Petra H. M.
Bueno de Mesquita, H. Bas
Weiderpass, Elisabete
Huerta Castaño, José María
Barricarte, Aurelio
Sánchez, María José
Dorronsoro, Miren
Quirós, J. Ramón
Agudo, Antonio
Sjöberg, Klas
Ohlsson, Bodil
Hemmingsson, Oskar
Werner, Mårten
Bradbury, Kathryn E.
Khaw, Kay-Tee
Wareham, Nicholas J.
Tsilidis, Konstantinos K.
Aune, Dagfinn
Scalbert, Augustin
Romieu, Isabelle
Riboli, Elio
Jenab, Mazda
Keywords: Càncer de fetge
Liver cancer
Issue Date: 4-Apr-2017
Publisher: Biomed Central
Abstract: Background: Leakage of bacterial products across the gut barrier may play a role in liver diseases which often precede the development of liver cancer. However, human studies, particularly from prospective settings, are lacking. Methods: We used a case-control study design nested within a large prospective cohort to assess the association between circulating levels of anti-lipopolysaccharide (LPS) and anti-flagellin immunoglobulin A (IgA) and G (IgG) (reflecting long-term exposures to LPS and flagellin, respectively) and risk of hepatocellular carcinoma. A total of 139 men and women diagnosed with hepatocellular carcinoma between 1992 and 2010 were matched to 139 control subjects. Multivariable rate ratios (RRs), including adjustment for potential confounders, hepatitis B/C positivity, and degree of liver dysfunction, were calculated with conditional logistic regression. Results: Antibody response to LPS and flagellin was associated with a statistically significant increase in the risk of hepatocellular carcinoma (highest vs. lowest quartile: RR = 11.76, 95% confidence interval = 1.70-81.40; P-trend = 0.021). This finding did not vary substantially by time from enrollment to diagnosis, and did not change after adjustment for chronic infection with hepatitis B and C viruses. Conclusions: These novel findings, based on exposures up to several years prior to diagnosis, support a role for gut-derived bacterial products in hepatocellular carcinoma development. Further study into the role of gut barrier failure and exposure to bacterial products in liver diseases is warranted.
Note: Reproducció del document publicat a:
It is part of: BMC Medicine, 2017, vol. 15, num. 72
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
FedirkoV.pdf1.04 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons